THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [4.21] ID: TIP-MED-000065

Semaglutide (Oral & Subcutaneous GLP-1 Receptor Agonist)

Active Ingredient / Scientific Identity: Semaglutide • Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist (Schedule H)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Semaglutide (Oral & Subcutaneous GLP-1 Receptor Agonist) ([4.21] | ID: TIP-MED-000065) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/4-21-semaglutide-oral-subcutaneous-glp-1-receptor-agonist/
Generic / Entity NameSemaglutide (Oral & Subcutaneous GLP-1 Receptor Agonist) ([4.21])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassGlucagon-Like Peptide-1 (GLP-1) Receptor Agonist (Schedule H)
Available Dosage FormsOral Tablets (co-formulated with SNAC absorption enhancer): 3 mg, 7 mg, 14 mg. SC Pre-Filled Pen: 0.25 mg, 0.5
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal: No dose adjustment required across CKD stages (protective in diabetic kidney disease, FLOW trial), but prevent dehydra
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Semaglutide (Oral & Subcutaneous GLP-1 Receptor Agonist) (TIP-MED-000065, Reference Code [4.21]) is classified under Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.21], p. 55): Oral Tablets: Rybelsus (Novo Nordisk). Subcutaneous Pen: Ozempic, Wegovy (Novo Nordisk) — Strengths & Dosage Forms: Oral Tablets (co-formulated with SNAC absorption enhancer): 3 mg, 7 mg, 14 mg. SC Pre-Filled Pen: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg Weekly
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.21], p. 55): Oral Tablets: Rybelsus (Novo Nordisk). Subcutaneous Pen: Ozempic, Wegovy (Novo Nordisk) — Strengths & Dosage Forms: Oral Tablets (co-formulated with SNAC absorption enhancer): 3 mg, 7 mg, 14 mg. SC Pre-Filled Pen: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg Weekly
Dosage Forms & Available Strengths:
Oral Tablets (co-formulated with SNAC absorption enhancer): 3 mg, 7 mg, 14 mg. SC Pre-Filled Pen: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg Weekly
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist (Schedule H) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist (Schedule H) for Type 2 Diabetes Mellitus with established ASCVD, high CV risk, CKD, or obesity (reduces MACE, heart failure, and nephropathy progression).

4. Therapeutic Indications & Evidence-Supported Uses

  • Type 2 Diabetes Mellitus with established ASCVD, high CV risk, CKD, or obesity (reduces MACE, heart failure, and nephropathy progression)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Oral (Rybelsus): Start 3 mg OD x 30 days (initiation dose only), then increase to 7 mg OD; after >=30 days may increase to 14 mg OD. SC (Ozempic): Start 0.25 mg SC Once Weekly x 4 weeks, then 0.5 mg Weekly (max 1–2 mg Weekly)

Administration & Meal Timing: ORAL RYBELSUS STRICT RULE: Take at 6:00 AM on a completely EMPTY STOMACH with NO MORE THAN 120 mL (half a glass) of plain water ONLY; swallow whole; wait AT LEAST 30 MINUTES before eating, drinking tea/coffee/more water, or taking any other oral medicine! | Oral: First thing upon waking (Slot 1, empty stomach). SC Pen: Once Weekly on the same day each week

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: No dose adjustment required across CKD stages (protective in diabetic kidney disease, FLOW trial), but prevent dehydration from vomiting. Hepatic: No adjustment required
Elimination & Renal Adjustment:
Renal: No dose adjustment required across CKD stages (protective in diabetic kidney disease, FLOW trial), but prevent dehydration from vomiting. Hepatic: No adjustment required
Hepatic Impairment Considerations:
Renal: No dose adjustment required across CKD stages (protective in diabetic kidney disease, FLOW trial), but prevent dehydration from vomiting. Hepatic: No adjustment required

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CONTRAINDICATED in personal or family history of Medullary Thyroid Carcinoma (MTC), Multiple Endocrine Neoplasia type 2 (MEN 2), pregnancy (stop >=2 months before conception!), Type 1 DM, DKA, and prior pancreatitis

Key Clinical Precautions: Renal: No dose adjustment required across CKD stages (protective in diabetic kidney disease, FLOW trial), but prevent dehydration from vomiting. Hepatic: No adjustment required

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Dose-dependent nausea, vomiting, early satiety, diarrhoea, constipation, decreased appetite (most common during initiation and dose escalation)
  • Acute pancreatitis, gallbladder disease (cholelithiasis/cholecystitis), worsening of pre-existing diabetic retinopathy, AKI from dehydration, pulmonary aspiration during general anaesthesia (delayed gastric emptying!)
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Delays gastric emptying -> increases Levothyroxine exposure by 33% (monitor TSH!); reduce Sulfonylurea or Insulin dose by 20–30% to prevent hypoglycaemia

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: For Rybelsus tablets: keep in original blister until swallowing with ONLY half a glass (120 mL) of plain water and wait 30 full minutes before tea, breakfast, or other pills; inform anaesthetist before any surgery/endoscopy
  • Meal & Clock Timing Instruction: ORAL RYBELSUS STRICT RULE: Take at 6:00 AM on a completely EMPTY STOMACH with NO MORE THAN 120 mL (half a glass) of plain water ONLY; swallow whole; wait AT LEAST 30 MINUTES before eating, drinking tea/coffee/more water, or taking any other oral medicine! (Oral: First thing upon waking (Slot 1, empty stomach). SC Pen: Once Weekly on the same day each week)
  • Missed Dose Protocol: Oral: If missed, skip and take next morning. SC Weekly: If <=5 days since missed day, inject as soon as remembered; if >5 days, skip
  • Geriatric Dispensing Pearl: Monitor weight, hydration, and sarcopenia/frailty in older adults

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Tablets (co-formulated with SNAC absorption enhancer): 3 mg, 7 mg, 14 mg. SC Pre-Filled Pen: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg Weekly

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.21] (p. 55)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/4-21-semaglutide-oral-subcutaneous-glp-1-receptor-agonist/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.